Use of plerixafor in patients with Hodgkin lymphoma with poor mobilization of peripheral blood stem cells.
Shan
S
Yuan
Auayporn
A
Nademanee
Stephen J
SJ
Forman
Shirong
S
Wang
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000097:blood; D001596:Benzylamines; D002452:Cell Count; D000080027:Cyclams; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods; D014182:Transplantation, Autologous; D055815:Young Adult
D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor